Valeant Pharmaceuticals International, Inc. (VRX) reported a second-quarter net loss attributable to company of $53.0 million or $0.15 per share, compared to profit of $125.8 million or $0.37 per share, last year. Cash earnings per share was $2.56, for the quarter. Excluding negative impact of foreign exchange and the negative contribution of Salix, Cash EPS would have been $2.73.
Total revenue was $2.7 billion; an increase of 34% over the prior year. Excluding negative impact of foreign exchange and the contribution of Salix, revenue increased 27% over the prior year. Same store sales organic growth was 19%.
The company increased full year 2015 total revenue guidance to $10.7 - $11.1 billion up from $10.4 - $10.6 billion. The company increased 2015 Cash EPS to $11.50 - $11.80.
For the third quarter, the company expects: total revenue of $2.6 - $2.8 billion; and cash EPS of $2.60 - $2.70 per share.
For the fourth quarter, the company expects: total revenue of $3.2 - $3.4 billion; and cash EPS of $3.98 - $4.18 per share.
For comments and feedback contact: editorial@rttnews.com
Business News